RxDoctor Payments DataLook up a doctor →

Lisa Connery, MD

Family Medicine · Norman, OKNPI 1205828977

Payments from drug & device makers

$15,603,335in general payments, 2019–2025

Across 2,115 payments — averaging $7377.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$11.6M
  • Boehringer Ingelheim$965K
  • Pfizer$865K
  • Amgen$680K
  • Novo Nordisk AS$465K
  • Regeneron$220K
  • plus $820K from 46 others
$101,825in research payments, 2019–2025

Across 68 payments — averaging $1497.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$97K
  • Sanofi Pasteur Inc.$2K
  • Novo Nordisk AS$2K
  • AbbVie$894

What the payments were for

  • Consulting fees$34,30533%
  • Speaking & faculty fees$12,43012%
  • Travel & lodging$47,15545%
  • Food & beverage$11,26211%
  • Education$1460%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eli Lilly487$11,587,065
Boehringer Ingelheim64$965,476
Pfizer76$864,888
Amgen46$680,328
Novo Nordisk AS915$465,375
Regeneron41$220,163
AbbVie(2 entities)94$213,028
Vivus LLC9$103,624
Astrazeneca UK Limited12$85,175
Otsuka Pharmaceutical Development & Commercialization, Inc.2$79,115
Kowa Research Institute, Inc.32$71,004
Hoffmann-la Roche Limited6$59,356
Vertex2$47,364
Boehringer Ingelheim International GmbH121$33,048
Sanofi Pasteur Inc.4$26,976
Sekisui Diagnostics LLC1$21,547
F. Hoffmann-la Roche AG2$20,710
Lexicon Pharmaceuticals, Inc.6$16,453
Esperion Therapeutics, Inc.37$16,429
AstraZeneca24$13,375
Eli Lilly Export S.A. Puerto Rico Branch2$5,628
Genentech, Inc.1$1,800
Novartis3$1,274
Merck7$1,199
Zealand Pharma A/s2$866
Lilly USA, LLC31$413
Takeda Pharmaceuticals U.S.A., Inc.10$182
Novo Nordisk12$176
Radius Health, Inc.7$151
Genentech USA, Inc.1$150
Astellas Pharma US Inc3$100
Teva Pharmaceuticals USA, Inc.6$95
Idorsia Pharmaceuticals US Inc5$82
Corcept Therapeutics5$80
Axsome Therapeutics, Inc.4$77
GSK5$69
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC4$54
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)3$53
Amarin Pharma, Inc.3$53
Therapeuticsmd, Inc.3$44
Bayer2$35
Dexcom, Inc.2$33
Exact Sciences2$32
Biohaven Pharmaceutical Holding Company Ltd.2$32
Kowa Pharmaceuticals America, Inc.2$31
Almatica Pharma LLC1$28
Cequr Corporation1$20
Ultragenyx Pharmaceutical Inc.1$19
Currax Pharmaceuticals LLC1$18
Azurity Pharmaceuticals, Inc.1$17
Ascendis Pharma Endocrinology Inc1$15
Biohaven Pharmaceuticals, Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,603,335 in reported general payments places this provider in the 95th percentile of 1,730 family medicine providers in Oklahoma.

See all family medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$64,888
Medicare patients
173
Services billed
638

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide70$81,948
ForteoTeriparatide13$53,861
JardianceEmpagliflozin49$43,844
EliquisApixaban39$41,483
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$26,411
MyrbetriqMirabegron17$20,433
QuliptaAtogepant13$16,485
FarxigaDapagliflozin Propanediol11$13,751
OzempicSemaglutide11$10,184
Dexlansoprazole DrDexlansoprazole20$9,053
Atorvastatin Calcium329$6,669
SavellaMilnacipran Hcl11$5,397
Breo ElliptaFluticasone/Vilanterol11$4,639
Duloxetine Hcl138$4,464
NexletolBempedoic Acid11$4,332

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Forteo$413$135,80983 claims
Boehringer IngelheimJardiance$965,476$43,84449 claims
PfizerEliquis$864,888$41,48339 claims
GSKTrelegy Ellipta, Breo Ellipta, Shingrix$69$34,99964 claims
AbbVieQulipta, Savella, Synthroid$213,028$22,83136 claims
Astellas Pharma US IncMyrbetriq$100$20,43317 claims
AstraZenecaFarxiga$13,375$13,75111 claims
Novo NordiskOzempic$176$10,18411 claims
Esperion Therapeutics, Inc.Nexletol$16,429$4,33211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,730 family medicine providers in Oklahoma.

Other family medicine in Norman

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →